 |
|
|
|
June 2006 Cover
|
|
Canadian Biotech firm Anormed Inc. said early clinical data from a dosing study found that half of the HIV patients administered its drug AMD070 showed a response. Four of the eight patients experienced significant
viral load reductions after taking the treatment, and no serious safety concerns have occurred so far, the company said. AMD070 targets the CXCR4 receptor which HIV uses to invade healthy cells. About 40 percent of
patients have the HIV type that binds to this receptor. The company hopes to start mid-stage clinical trials by year's end.
Editor's Note: from the Associated Press
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
